Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021
10/07/2021 - 04:01 PM
SAN DIEGO --(BUSINESS WIRE)--
Gossamer Bio, Inc. Monday, October 11, 2021 , at 2:30 pm ET to announce its next clinical product candidates.
Gossamer management will present and discuss its forthcoming additions to its clinical product candidate pipeline. As part of the event, Gossamer Bio management will be available for questions.
Conference Call and Webcast
Gossamer will host a conference call and live audio webcast at 2:30 pm ET on Monday, October 11 . The live audio webcast may be accessed through the “Events / Presentations” page in the “Investors” section of the Company's website at www.gossamerbio.com . Alternatively, the conference call may be accessed through the following:
Conference ID: 4165598
Domestic Dial -in Number:International Dial-in Number: (929) 517-9782
Live Webcast: https://edge.media-server.com/mmc/p/4jha6kh9
A replay of the audio webcast will be available for 30 days on the “Investors” section of the Company's website, www.gossamerbio.com .
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.
View source version on businesswire.com : https://www.businesswire.com/news/home/20211007005849/en/
For Investors and Media:
Bryan Giraudo , Chief Operating Officer & Chief Financial Officer
ir@gossamerbio.com
Source: Gossamer Bio, Inc.
GOSS Rankings
#5513 Ranked by Stock Gains
GOSS Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Pharmaceuticals: Major, Health Technology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
San Diego
About GOSS
gossamer bio is a san diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. founded by the former receptos executive team, gossamer bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
